Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
58
resultados
Última actualización
21/11/2025 [07:19:00]
Resultados 25 a 50 de 58
Resumen de: US2025325551A1
A method of diagnosing Alzheimer's disease and related dementias (ADRD) in a patient comprising obtaining a plasma sample from the patient; determining a level of a biochemical sulfide in the plasma sample from the subject by trapping volatilized H2S in the plasma sample using alkaline buffer with monobromobiamine, and detecting the level of biochemical sulfide in the plasma sample, the biochemical sulfide being one of acid-labile sulfide, bound sulfide, and total sulfide; and diagnosing the patient with ADRD when the level of the biochemical sulfide is at least an elevated threshold level for the biochemical sulfide.
Resumen de: AU2024249796A1
The present invention relates to protein markers relevant to mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially those detectable in blood samples. Thus, methods and compositions are provided for risk assessment and early diagnosis of MCI and AD based on the analysis of these protein markers. Further provided are methods and compositions useful for evaluating the efficacy of a therapy for MCI or AD.
Resumen de: MX2025003197A
The disclosure relates to lemborexant, a dual orexin receptor antagonist, and compositions and methods for use in treatment of Alzheimer's disease (AD), e.g., in a subject who has AD or who is at risk for developing AD.
Resumen de: US2025320293A1
Provided is an anti-TREM2 single-domain antibody, consisting of heavy chains including CDR1 represented by any one of SEQ ID NOs: 34-40, CDR2 represented by any one of SEQ ID NOs: 41-45, and CDR3 represented by any one of SEQ ID NOs: 46-50. The single-domain antibody has good affinity with TREM2.
Resumen de: US2025320495A1
Provided herein are methods for modulating follistatin, such as inhibiting follistatin, suppressing the production of follistatin, reducing the level of follistatin, inhibiting the function of follistatin, or a combination thereof. The method can include administration of a compound that acts to modulate follistatin. In one embodiment, the compound is administered to a patient having or at risk or having a disease or condition selected from diabetes, pre-diabetes, metabolic syndrome, insulin resistance, dementia, and obesity, and optionally the disease or condition is prevented, treated, ameliorated, or a combination thereof.
Resumen de: EP4632384A1
An object is to determine a cognitive dysfunction stage of a subject early. The present disclosure provides a method for determining a cognitive dysfunction stage of a subject comprising: a step of measuring a level or amount of at least one of drebrin A or drebrin A-derived molecules in a biological sample collected from the subject; and a step of determining a cognitive dysfunction stage of the subject based on the level or amount.
Resumen de: WO2024213092A1
The present invention relates to protein markers relevant to mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially those detectable in blood samples. Thus, methods and compositions are provided for risk assessment and early diagnosis of MCI and AD based on the analysis of these protein markers. Further provided are methods and compositions useful for evaluating the efficacy of a therapy for MCI or AD.
Resumen de: WO2025210040A1
The present invention provides a cell model to study Tau protein related diseases.
Resumen de: WO2025212713A1
Methods described herein provide procedures that can be used to rapidly screen drugs for high probability of effectiveness as therapy for amyloid associated neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's disease, and prion-associated diseases by detecting size and/or aggregation of phage incubated with a target compound. The data generated indicate that bacteriophage or phage capsid subunits can switch conformation to a conformation that mimics the neurodegenerative disease-causing conformation of amyloid proteins. This switch has been observed by incubation of bacteriophage T4 with methylene blue, a compound for which literature data indicates has anti-AD activity.
Resumen de: MX2025005880A
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Resumen de: WO2024061128A1
Disclosed in the present invention is a use of a reagent for measuring the expression level of discoidin domain receptor 2 (DDR2) in the preparation of a kit for diagnosing neurodegenerative diseases of a subject. If the level of DDR2 in a sample from the subject is higher than the level of a control subject not suffering from the diseases, it indicates that the subject suffers from neurodegenerative diseases. Also disclosed in the present invention are a kit and method for diagnosing neurodegenerative diseases, and a computer readable medium. According to the present invention, neurodegenerative diseases are efficiently and accurately diagnosed by measuring DDR2.
Resumen de: AU2023351193A1
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
Resumen de: US2025306039A1
Provided are methods of phospho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, and treatment. Novel p-tau sites, p-tau198, p-tauS356, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.
Resumen de: US2025305982A1
The present disclosure provides devices for the detection and/or quantification of neurotoxic amyloid-type protein aggregates, comprising a doxycycline derivative immobilized on an appropriate surface, as well as electrochemical and immunochemical methods associated to the use of such devices.
Resumen de: US2025306040A1
Methods for detecting or quantifying amylin-beta amyloid (Aβ) hetero-oligomers (amylin-Aβ aggregate) are provided. Anti-amylin and anti-Aβ antibodies which recognize epitopes that are distinct from high affinity binding sites between amylin peptide and Aβ peptide can be utilized as capture and detection antibodies, respectively, in a sandwich enzyme-linked immunosorbent assay (ELISA) to provide detection and quantification of amylin-Aβ aggregate present in a biological sample, such as blood or brain tissue. Kits useful for the detection and the quantification of amylin-Aβ aggregate are also provided.
Resumen de: US2025306037A1
The present disclosure relates to methods useful to identify subjects having an increased risk for conversion to mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and/or stage a subject prior to the onset of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and/or identify subjects with Aβ amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aβ amyloidosis, as well as methods for treating subjects diagnosed with Aβ amyloidosis by the methods disclosed herein.
Resumen de: WO2025208162A1
Methods of differentiating and quantifying modifications in the tau protein in bio-fluids to detect, classify, and treat a plurality of tauopathies are disclosed. The disclosed methods include liquid chromatographic mass spectrometric analyses on isolated tau protein fragments to identify and quantify deamidated or isomerized asparagines or aspartic acids indicative of a neuropathology associated with a tauopathy.
Resumen de: CN120559249A
The present invention provides compounds and methods for targeting human tau, particularly human tau phosphorylated at threonine 217 and tau isoforms expressed only in CNS, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications for use in the field of neurodegenerative diseases such as AD, PSP and FTD.
Resumen de: US2024197682A1
A method of inhibiting propagation of protein misfolding associated with a neurological disease, is carried out by contacting an environment populated with a propagating amyloid conformation of a protein (prion) associated with a neurological disease with molecules which binds multiple adjacent sites of the protein assemblies and allowing the molecules to bind multiple cites of the protein assemblies; and thereby impeding propagation of the disease-associated conformation of the protein in the environment. Drug/prion complexes are formed and uses of the drugs in detection and treatment of neurodegenerative diseases are disclosed.
Resumen de: WO2024166074A1
The present invention relates to a method of isolating exosomes from human immature dental pulp stem cell (hIDPSC) cultures that is scalable. The present invention also provides pharmaceutical compositions comprising exosomes and methods of using these pharmaceutical compositions to treat a neurological disease or condition, infectious disease, or cancer.
Resumen de: TW202513585A
Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.
Resumen de: WO2024194276A1
The present invention is directed to methods for determining the level of PAM and/or its isoforms and/or fragments thereof in a bodily fluid or a tissue sample using an assay, wherein said assay is comprising at least one binder that is directed to a conformational epitope of PAM, and its use for diagnostic purpose.
Resumen de: NZ750096A
A method of detecting the presence of alpha-synuclein aggregation in a biological sample is provided whereby a biological sample is mixed with a reaction sample comprising a population of beads, a fluorophore adapted to bind to protein aggregates and to increase fluorescence when bound to protein aggregates, and alpha-synuclein or a fragment or variant thereof to form a reaction mixture, the reaction mixture is illuminated and at the same time incubated with intermittent agitation cycles, wherein a significant increase in the fluorescence of the reaction mixture during incubation is indicative of the presence of aggregates of alpha-synuclein in the biological sample. Method of diagnosing alpha-synucleinopathies such as Parkinson’s disease or Dementia with Lewy Bodies.
Resumen de: WO2025199015A1
This invention provides skin cell fibroblast- and blood-based methods for determining whether a human subject has a gene expression profile characteristic of AD. This invention also provides related methods for determining whether a demented human subject is afflicted with AD or non-ADD, and for determining whether a non-demented human subject has an increased likelihood of becoming afflicted with AD.
Nº publicación: US2025298023A1 25/09/2025
Solicitante:
UNIV DEGLI STUDI DI MILANO [IT]
UNIVERSITA' DEGLI STUDI DI MILANO
Resumen de: US2025298023A1
A method for diagnosing neurodegenerative diseases, the method including measuring the JNK3 levels in a biological sample selected from plasma, CSF, and saliva. The method also includes measuring P-JNK3.
BOPI
Sede Electrónica
